KNSA's Quality Score fell 4 points on Fri, Oct 30, to 21. Buying volume slipped off its 20-day high (3 chart checks stopped). 1 more reason, for Pro members.
Follow KNSA's trial news. Pro members can get an alert when Kiniksa Pharmaceuticals International files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 22% on Oct 27, and still 26% over its Oct 26 close.
“The increase in COGS expenses was primarily due to costs associated with increased sales of ARCALYST.”
| Sales tripled | $220.2M → $677.6M in 3 years |
| Latest filing | 8-K, Oct 27 |
After its last 4 reports it closed +15.6% on average, higher 3 of 4 times.
Chief Accounting Officer Michael R Megna sold 4,600 shares on Sep 3, under a planned sale. 16 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Exceptionalfor quality, not price, 6 of 14 chart checks firingWhat the Quality Score means
KNSA is #2 of 291 by Quality Score.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score |
Expected to report Tue Feb 23, before the open (in 113 days). Expected.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $286.0M, 58% more than a year ago; a profit of $0.56 a share, from $0.23.
“The increase in COGS expenses was primarily due to costs associated with increased sales of ARCALYST.”
KNSA's results filing gives no sales by line in a table we read.
| Measure | Figure |
|---|---|
| ARCALYST net product revenue | $1.045B to $1.050B |
“Kiniksa expects its current operating plan to remain cash flow positive on an annual basis.”
From its results filing (SEC filing · Oct 27)
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Oct 27, 2026 | +16.5% | +22.2% | +25.7% |
| Jul 28, 2026 | +10.3% | +25.0% | +15.5% |
| Apr 28, 2026 | +8.2% | +23.5% | +32.1% |
Sales grew every year from 2022 to 2025, to $678M. It turned a profit in 2025 after a loss in 2024.
One insider sold $299K across 1 filing in the last 6 months. No open-market buys on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: KNSA is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
“The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products.”
KNSA scores 21 today, which Breakaway calls Exceptional. It is #2 of 291 in Biotech by Quality Score, with 6 of 14 chart checks firing. Up 22% on Oct 27, and still 26% over its Oct 26 close. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
KNSA scores 21 today, which Breakaway calls Exceptional (20 or more). That is #2 of 291 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind KNSA's 21.
One insider sold $299K across 1 filing in the last 6 months. No open-market buys on record. The newest is G. Bradley Cole, Director, who sold $299K on Jul 29.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.